×
  • Home
  • Product Development
    • Product development
    • Technology
    • BP-C1
    • BP-C2
    • Publications
  • Early access
  • About us
    • About us
    • The Team
    • Careers
  • News
  • Home
  • Product Development
    • Product development
    • Technology
    • BP-C1
    • BP-C2
    • Publications
  • Early access
  • About us
    • About us
    • The Team
    • Careers
  • News

BP-C2: Gastrointestinal Acute Radiation Syndrome Radiomitigative Potential in C57BL/6J Mouse Model

  • Oct 19, 2020
  • By Meabco
  • In News

BPC2 Gastrointestinal Acute Radiation Syndrome PDF

Share:

Latest news

  • Meabco’s Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice
  • BP-C2: Gastrointestinal Acute Radiation Syndrome Radiomitigative Potential in C57BL/6J Mouse Model
  • Meabco Awarded a $5.9 Million US Government Contract to Advance its BP-C2 compound as a Medical Countermeasure for Cutaneous Radiation Injuries
Meabco logo

Business adress’

HEAD OFFICE
Richard Mortensens Vej 61
DK-2300 Copenhagen, Denmark

US OFFICE
875 N Michigan Ave
John Hancock Center
Suite 3950
Chicago Il 60611, USA

Contact info

Telephone Head office: +45 32 46 03 70
E-mail: info@meabco.com

Telephone US office: +1 (312) 239 6322
E-mail: info@meabco.com

Latest news

  • Meabco’s Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice

Powered by ATAK